UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reply to Achieng and Riedel

The Journal of infectious diseases, 2019-01, Vol.219 (1), p.167-169

2019

Volltextzugriff (PDF)

Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults

Expert opinion on pharmacotherapy, 2021-07, Vol.22 (10), p.1245-1251

Mesplède, Thibault

2021

Volltextzugriff (PDF)

Antimalarial drugs and their metabolites are potent Zika virus inhibitors

Journal of medical virology, 2019-07, Vol.91 (7), p.1182-1190

2019

Volltextzugriff (PDF)

Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update

Expert opinion on investigational drugs, 2018-12, Vol.27 (12), p.951-962

2018

Volltextzugriff (PDF)

The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities

Journal of medical virology, 2018-05, Vol.90 (5), p.796-802

2018

Volltextzugriff (PDF)

Erratum for Mesplède et al., "The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration"

mBio, 2018-09, Vol.9 (5)

2018

Volltextzugriff (PDF)

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

Journal of Virology, 2012-03, Vol.86 (5), p.2696-2705

2012

Volltextzugriff (PDF)

Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of Podocarpus imbricatus

Journal of natural products (Washington, D.C.), 2020-08, Vol.83 (8), p.2416-2424

2020

Volltextzugriff (PDF)

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

Drugs in Context, 2020-03, Vol.9, p.1-11

2020

Volltextzugriff (PDF)

The R263K resistance substitution decreases levels of integrated HIV DNA over time

Journal of Virus Eradication, 2016-05, Vol.2, p.12-12

2016

Volltextzugriff (PDF)

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

Expert opinion on pharmacotherapy, 2019-03, Vol.20 (4), p.385-397

2019

Volltextzugriff (PDF)

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase

Journal of virology, 2015-03, Vol.89 (6), p.3163-3175

2015

Volltextzugriff (PDF)

Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification

Clinical infectious diseases, 2024-07, Vol.79 (1), p.198-201

2024

Volltextzugriff (PDF)

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

Journal of antimicrobial chemotherapy, 2016-08, Vol.71 (8), p.2083-2088

2016

Volltextzugriff (PDF)

Investigational drugs for HIV: trends, opportunities and key players

Expert opinion on investigational drugs, 2023-02, Vol.32 (2), p.127-139

2023

Volltextzugriff (PDF)

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

Antimicrobial agents and chemotherapy, 2023-05, Vol.67 (5), p.e0138622-e0138622

2023

Volltextzugriff (PDF)

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

Journal of antimicrobial chemotherapy, 2016-07, Vol.71 (7), p.1948-1953

2016

Volltextzugriff (PDF)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

Viruses, 2015-07, Vol.7 (7), p.3703-3718

2015

Volltextzugriff (PDF)

HIV‐1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV‐1 group M

Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19738-n/a

2014

Volltextzugriff (PDF)

Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor

Antiviral chemistry & chemotherapy, 2015-02, Vol.24 (1), p.28-38

2015

Volltextzugriff (PDF)

HIV drug resistance against strand transfer integrase inhibitors

Retrovirology, 2017-06, Vol.14 (1), p.36-36, Article 36

2017

Volltextzugriff (PDF)

The latest evidence for possible HIV-1 curative strategies

Drugs in Context, 2018, Vol.7, p.212522-14

2018

Volltextzugriff (PDF)

p53 Degradation Activity, Expression, and Subcellular Localization of E6 Proteins from 29 Human Papillomavirus Genotypes

Journal of Virology, 2012-01, Vol.86 (1), p.94-107

2012

Volltextzugriff (PDF)

Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1

Expert opinion on investigational drugs, 2020-03, Vol.29 (3), p.273-283

2020

Volltextzugriff (PDF)

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors

Infection, genetics and evolution, 2016-12, Vol.46, p.286-291

2016

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(121)
Buchkapitel
(1)

Sprache

Englisch
(120)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(95)
Life Sciences & Biomedicine
(92)
Humans
(74)
Virology
(42)
Human Immunodeficiency Virus
(38)
Hiv
(36)
Infectious Diseases
(35)
Hiv-1 - Drug Effects
(32)
Hiv-1 - Genetics
(32)
Microbiology
(32)
Hiv Integrase - Genetics
(31)
Heterocyclic Compounds, 3-Ring - Pharmacology
(30)
Pharmacology & Pharmacy
(30)
Drug Resistance, Viral
(29)
Hiv Integrase Inhibitors - Pharmacology
(29)
Hiv Infections - Drug Therapy
(28)
Drug Resistance
(26)
Hiv Infections - Virology
(26)
Mutation
(26)
Hiv-1 - Enzymology
(24)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reply to Achieng and Riedel

Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults

Antimalarial drugs and their metabolites are potent Zika virus inhibitors

Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update

The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities

Erratum for Mesplède et al., "The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration"

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of Podocarpus imbricatus

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

The R263K resistance substitution decreases levels of integrated HIV DNA over time

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase

Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

Investigational drugs for HIV: trends, opportunities and key players

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

HIV‐1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV‐1 group M

Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor

HIV drug resistance against strand transfer integrase inhibitors

The latest evidence for possible HIV-1 curative strategies

p53 Degradation Activity, Expression, and Subcellular Localization of E6 Proteins from 29 Human Papillomavirus Genotypes

Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors

Suchergebnisse filtern